Current Knowledge and Perspectives for Pharmacological Treatment in OSA

Sébastien Baillieul, Renaud Tamisier, Danny J. Eckert, Jean-Louis Pépin

Research output: Contribution to journalEditorial

1 Citation (Scopus)


Obstructive sleep apnoea (OSA) impacts approximatively one billion people globally,1, 2 and is associated with detrimental cardiovascular, metabolic, and neurocognitive consequences, as well as bothersome diurnal symptoms that adversely impact daytime function and work productivity.3 It is now acknowledged that OSA is a highly heterogeneous condition encompassing various endophenotypes, defined as the association of clinical manifestations of OSA (phenotypes) and their underlying pathophysiological traits (endotypes).4 Identification of these endophenotypes is a prerequisite for risk stratification and prognosis anticipation.
Original languageEnglish
Pages (from-to)681-684
Number of pages4
JournalArchivos de Bronconeumologia
Issue number10
Publication statusPublished - Oct 2022


  • Obstructive sleep apnoea (OSA)
  • Pharmacological Treatment
  • Editorial


Dive into the research topics of 'Current Knowledge and Perspectives for Pharmacological Treatment in OSA'. Together they form a unique fingerprint.

Cite this